Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Are Biosimilars the Key to Access, in Practice?

This ESMO COLLOQUIUM took place during ESMO 2018 Congress, 21.10.2018


  • M. Weiss, Bonn, Germany
  • E. De Vries, Groningen, Netherlands


  • E. De Vries (Groningen, Netherlands)
Acceptance of oncology biosimilars in supportive care: a success story
  • M. Weiss (Bonn, Germany)


Existing challenges for uptake of oncology biosimilars – ESMO survey results
  • M. Vyas (Lugano, Switzerland)
One year on – state of play in the EU on oncology biosimilars
  • M. Aitken (Parsippany, United States of America)
Supplementary Protection Certificates & their potential impact on availability of biosimilars
  • R. Romandini (Freiburg im Breisgau, Germany)
Panel with industry representatives
  • J. Coindreau (New York City, United States of America)
  • J. Hippenmeyer (Zug, Switzerland)
  • A. Krendyukov (Holzkirchen, Germany)
  • A. Roediger (Kriens, Switzerland)
  • E. De Vries (Groningen, Netherlands)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.